MUMBAI, India, Aug. 17 -- Intellectual Property India has published a patent application (202617084512 A) filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services; University Of Chicago; Schrodinger, Inc.; and Curia Global, Inc. on July 09, 2026, for Triazolone Inhibitors Of Nicotinamide N-Methyltransferase And Their Therapeutic Uses.
Inventors include Patnaik, Samarjit; Shrimp, Jonathan Harold; Sun, Hongmao; Marugan, Juan Jose; Kong, Ke; Liu, Li; Hall, Matthew D.; Flint, Andrew John; Shen, Min; Hanson, Quinlin M.; Cheng, Chih-Chien; Yang, Tae Gyun; Moore, William Jay; Heide, Janna; Lengyel, Ernst; Janiszewski, John Stephen; Stott, Gordon; Green, Neal; Eckert, Mark; Allega, Maria Francesca; White, Andre; and Wolf, Mark Allan.
The application for the patent was published on August 14, 2026, under issue no. 33/2026.
Abstract: The disclosure provides potent, selective and orally bioavailable inhibitors of nicotinamide N-methyltransferase (NNMT) which have a triazolone-piperidine scaffold. The NNMT inhibitors are useful for treating tumors and cancers, metabolic disorders and liver disorders.
Disclaimer: Curated by HT Syndication.
